- Home
- BRLT vs MURA Comparison
BRLT vs MURA Comparison
Compare BRLT & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRLT
- MURA
- Stock Information
- Founded
- BRLT 2005
- MURA 2013
- Country
- BRLT United States
- MURA Ireland
- Employees
- BRLT N/A
- MURA N/A
- Industry
- BRLT Consumer Specialties
- MURA
- Sector
- BRLT Consumer Discretionary
- MURA
- Exchange
- BRLT Nasdaq
- MURA Nasdaq
- Market Cap
- BRLT 36.6M
- MURA 36.0M
- IPO Year
- BRLT 2021
- MURA N/A
- Fundamental
- Price
- BRLT $2.16
- MURA $2.09
- Analyst Decision
- BRLT Hold
- MURA Buy
- Analyst Count
- BRLT 2
- MURA 2
- Target Price
- BRLT $1.80
- MURA $6.00
- AVG Volume (30 Days)
- BRLT 117.3K
- MURA 126.0K
- Earning Date
- BRLT 11-05-2025
- MURA 11-06-2025
- Dividend Yield
- BRLT N/A
- MURA N/A
- EPS Growth
- BRLT N/A
- MURA N/A
- EPS
- BRLT N/A
- MURA N/A
- Revenue
- BRLT $432,597,000.00
- MURA N/A
- Revenue This Year
- BRLT $5.48
- MURA N/A
- Revenue Next Year
- BRLT $3.45
- MURA N/A
- P/E Ratio
- BRLT N/A
- MURA N/A
- Revenue Growth
- BRLT 1.31
- MURA N/A
- 52 Week Low
- BRLT $1.25
- MURA $0.95
- 52 Week High
- BRLT $3.10
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- BRLT 41.82
- MURA 54.04
- Support Level
- BRLT $2.23
- MURA $2.06
- Resistance Level
- BRLT $2.90
- MURA $2.10
- Average True Range (ATR)
- BRLT 0.23
- MURA 0.01
- MACD
- BRLT -0.03
- MURA -0.00
- Stochastic Oscillator
- BRLT 6.49
- MURA 75.00
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.